The rescheduling of medical cannabis from Schedule I to Schedule III is the most consequential shift in U.S. controlled substance policy in more than fifty years. For those of us building the infrastructure for legal, ethical psychedelic medicine, it is also the clearest map yet of where this field is headed, and how much work there is to do before we get there.
At the National Psychedelics Association, we sit at the intersection of the two things this policy shift makes most visible: the advocacy work needed to change how these substances are classified, and the practical business infrastructure that must exist before any clinical ecosystem can function at scale. Cannabis just ran that experiment for us. Here is what it shows.
What Rescheduling Actually Changes, and What It Doesn’t
It is worth being precise, because the headlines have not always been.
The federal rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act is a significant, but widely misunderstood, policy shift. The process is still technically ongoing: President Trump signed an executive order in December 2025 directing the Attorney General to expedite and complete the rescheduling process, and on April 23, 2026, Trump reclassified medical cannabis companies specifically, with a broader administrative hearing set for June 2026 to consider full rescheduling.
What Schedule III formally accomplishes is meaningful: it constitutes the federal government’s acknowledgment that a substance has “currently accepted medical use in treatment in the United States.” That is not a small thing. For over fifty years, cannabis shared its Schedule I classification with substances deemed to have no medical value whatsoever.
But rescheduling is not legalization, and it is not a complete solution. Banks remain exposed to potential money laundering charges, loss of FDIC insurance, and regulatory action for processing proceeds from cannabis sales, because the underlying activity is still federally illegal outside FDA-approved channels. Rescheduling alone does not guarantee that banks, payment processors, and insurers will instantly be willing to serve cannabis operators.
What it does do is change the direction of travel, decisively. And direction matters enormously when you are building infrastructure for a field that does not yet have it.
The Tax Problem That Has Crippled Cannabis, and What It Means for Psilocybin Clinics
The single most immediate material impact of cannabis rescheduling is the elimination of Section 280E of the Internal Revenue Code.
Cannabis operators currently pay federal income tax on gross income rather than net profit. While the cost of goods sold remains deductible, expenses like payroll, rent, marketing, insurance, utilities, and professional services are not, resulting in effective federal tax rates that routinely exceed 70% for cannabis businesses, versus the roughly 21% corporate rate other industries pay.
“The cannabis industry has paid outsized taxation for years,” says Beau Whitney, Chief Economist at Whitney Economics. “In 2025 alone, we found the industry will be charged an additional $2.3 billion on top of what other non-cannabis businesses would pay.”
Psilocybin service centers and clinics operating legally in Oregon and Colorado are not yet subject to 280E, but they are operating in an analogous regulatory gray zone. Like early cannabis operators, they face limited access to standard banking, difficulty securing professional insurance, and an institutional financial sector that has largely kept its distance. The cannabis experience makes clear what that costs, and how long it persists when the underlying regulatory framework is unresolved.
This is precisely why rescheduling psilocybin, from its current Schedule I classification, ideally to Schedule III, is not only an advocacy cause for the NPA. It is a prerequisite for a functioning clinical ecosystem.
Banking, Insurance, and the Infrastructure Gap
Cannabis’s path through financial services offers a precise preview of the challenges ahead for psychedelic medicine, and the opportunity for those who move early.
The Schedule I classification has historically deterred banks, payment processors, and insurers from serving the cannabis industry. Reclassification to Schedule III is expected to substantially increase the willingness of financial institutions to engage, improving banking access, safer business operations, and greater opportunities for institutional investment.
For insurance specifically, the picture is more nuanced. Capacity should improve, particularly in commercial property, business interruption, and D&O, supported by better access to banking and reinsurance capacity. But rescheduling will not make underwriting any easier. The underlying real-world risks, property, product safety, operational controls, compliance posture, supply chain integrity, do not become simpler because the schedule number has changed. As one legal expert put it, rescheduling is “a green light to proceed, cautiously and with both hands on the wheel.”
The psychedelic medicine sector has a choice that cannabis did not have at its equivalent moment: to build proper financial and insurance infrastructure before regulatory normalization catches up, rather than scrambling to retrofit it after. That is the opportunity the NPA’s commercial arm is designed to address, providing banking access, technology platforms, and insurance solutions to psilocybin clinics and facilitators operating legally in Oregon and Colorado today, so that when federal rescheduling arrives, the ecosystem is ready to scale responsibly.
According to Karan Wadhera, co-founder of Casa Verde Capital: “Rescheduling unlocks the removal of 280E, fundamentally reshaping cash flows, balance sheets, and valuation frameworks overnight. With normalized tax treatment, the industry can finally operate like a real consumer or healthcare category, opening the door to institutional capital, accelerated consumer adoption, and long-term global credibility.”
The psychedelic medicine sector should be building toward exactly that moment, not waiting for it.
The Parallel Trajectories Are Unmistakable
The structural comparison between cannabis’s regulatory journey and where psilocybin stands today is not speculative. It is visible in the policy record.
Cannabis moved from Schedule I, to state-led medical legalization, to growing clinical validation, to federal rescheduling momentum over roughly a decade. Psilocybin is following an identifiable version of the same arc. Oregon and Colorado have established licensed therapeutic access. The FDA has granted Breakthrough Therapy designation to multiple psilocybin compounds. The April 2026 executive order on psychedelic medicine has now directed the DEA to initiate rescheduling review after Phase 3 trial completion. And the Trump administration’s cannabis rescheduling process has established a clear procedural precedent for how a Schedule I substance transitions into a regulated medical framework.
As cannabis policy attorney Khurshid Khoja observed: “The science-, patient-, healthcare-first approach is winning in Washington right now. The psychedelic pathway, built on physician-led protocols, clinical research, and compassionate use frameworks, is actually a model cannabis advocates should be studying and adopting more aggressively.”
We would put it the other way around: the psychedelic medicine field has the advantage of studying what cannabis built, and building it better from the start.
What Early-Mover States Teach Us
Cannabis legalization did not wait for federal alignment. Oregon, Colorado, California, and others moved first and created the template. The federal system eventually followed, in part because those state programs generated data, normalized access, demonstrated safety, and built constituencies that proved too large to ignore.
Oregon and Colorado are doing exactly that for psilocybin right now. Licensed service centers are open. Facilitators are credentialed. Clients are being served. The clinical and operational data being generated in those states is the evidence base that federal rescheduling will ultimately rest on.
But those operators need the infrastructure to survive long enough to matter. They need banking they can actually use. They need professional liability coverage that reflects what they actually do. They need technology platforms built for the compliance requirements of a controlled-substance-adjacent clinical environment.
The cannabis industry had to build all of this after the fact, in crisis mode, against a 70% effective tax rate. Psilocybin medicine does not have to repeat that experience.
The Moment to Build Is Now
The rescheduling of medical cannabis is not directly about psilocybin. But it is deeply instructive about psilocybin’s future, and about the conditions required for that future to be equitable, sustainable, and clinically serious.
What cannabis demonstrates is that regulatory legitimacy is a precondition, not a guarantee. Legitimacy opens the door to institutional engagement. It does not build the room on the other side of it. That room, the banking relationships, the insurance capacity, the payment infrastructure, the professional standards, has to be built deliberately, by people who understand what this field is and what it requires.
At the NPA, we are doing that work on two tracks simultaneously. Our advocacy team is pursuing psilocybin rescheduling and Right to Try access through the courts and through Congress, because the classification question has to be resolved. And our commercial services arm is building the financial and operational infrastructure that licensed practitioners and clinics in Oregon and Colorado need today, so that when federal policy catches up, we are not starting from scratch.
Cannabis took decades to get the regulatory conditions right, and is still completing that work. Psychedelic medicine does not have to take that long. But it will, if we wait.
The direction of federal policy has never been clearer. The precedent has been set. The question now is who builds the infrastructure that makes psychedelic medicine work, and whether it gets built with the patients, practitioners, and values of this field at its center.
We are not waiting to find out.
Sources
Cover photo by Drew Beamer on Unsplash
The National Psychedelics Association advocates for psilocybin patients’ rights, federal rescheduling, and the development of ethical, accessible psychedelic medicine. We also provide banking, technology, and insurance solutions for licensed psilocybin service providers in Oregon and Colorado. Learn more at yournpa.org.
Let us know what you think